Overview

TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery

Status:
Not yet recruiting

Trial end date:
2022-10-31

Target enrollment:

Participant gender:

Summary

This study was phase IB-II clinical trial that designed to evaluate the efficacy and safety of docetaxel + atezolizumab + Herceptin sc plus pertuzumab(TAHP) plus adjuvant therapy of atezolizumab + trastuzumab + pertuzumab(AHP) after surgery in female patients with HER2-positive early breast cancer. Adjuvant AHP (atezolizumab + Herceptin SC + pertuzumab) will be continued for remaining 1 year. For non-p CR patients, they are going to treat with 4 cycles of AC rather than Taxane only before AHP adjuvant therapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Antibodies, Monoclonal
Atezolizumab
Docetaxel
Pertuzumab
Trastuzumab